Table 4.

CKD progression, overall and by CKD stage at first lab

CKD progression	Overall (%; 95% CI)	Stage 3a (eGFR 45–59) (%; 95% CI)	Stage 3b (eGFR 30–44) (%; 95% CI)	Stage 4 (eGFR 15–39) (%; 95% CI)	Stage 5 (eGFR <15) (%; 95% CI)
Overall
No change	48 895 (55.4%; 55.1% to 55.7%)	26 613 (68.6%; 68.2% to 69.1%)	10 590 (41.6%; 41.0% to 42.2%)	4811 (34.2%; 33.4% to 35.0%)	6881 (68.9%; 68.0% to 69.8%)
Improved*	16 237 (18.4%; 18.1% to 18.7%)	1227 (3.2%; 3.0% to 3.3%)	7344 (28.6%; 28.3% to 29.4%)	4561 (32.5%; 31.7% to 33.2%)	3105 (31.1%; 30.2% to 32.0%)
Progressed†	23 141 (26.2%; 25.9% to 26.5%)	10 930 (28.2%; 27.7% to 28.6%)	7528 (29.6%; 29.0% to 30.1%)	4683 (33.3%; 32.5% to 34.1%)	–
People living with diabetes
No change	5720 (50.6%; 49.7% to 51.5%)	2466 (56.9%; 55.4% to 58.4%)	1627 (43.6%; 42.0% to 45.2%)	930 (41.0%; 39.0% to 43.0%)	697 (71.6%; 68.7% to 74.4%)
Improved*	1431 (12.7%; 12.1% to 13.3%)	59 (1.4%; 1.0% to 1.7%)	612 (16.4%; 15.2% to 17.6%)	484 (21.3%; 19.7% to 23.1%)	276 (28.4%; 25.6% to 31.3%)
Progressed†	4152 (36.7%; 35.8% to 37.6%)	1807 (41.7%; 40.2% to 43.2%)	1490 (40.0%; 38.4% to 41.5%)	855 (37.7%; 35.7% to 39.7%)	–
People living without diabetes
No change	5866 (58.5%; 57.5% to 59.4%)	2250 (66.6%; 65.0% to 68.2%)	1218 (46.5%; 44.6% to 48.4%)	648 (35.7%; 33.5% to 37.9%)	1750 (78.8%; 77.1% to 80.4%)
Improved*	1646 (16.4%; 15.7% to 17.1%)	77 (2.3%; 1.8% to 2.8%)	630 (24.0%; 12.5% to 15.1%)	467 (25.7%; 23.8% to 27.8%)	472 (21.2%; 19.6% to 23.0%)
Progressed†	2523 (25.1%; 24.3% to 26.0%)	1051 (31.1%; 29.6% to 32.7%)	773 (29.5%; 27.8% to 31.3%)	699 (38.5%; 36.3% to 40.8%)	–

^*A patients CKD status was classified as ‘improved’ if they experienced an improvement in CKD stage and their eGFR function improved by at least 25% from baseline.

^†A patient’s CKD status was classified as ‘progressed’ if they experienced a drop in CKD stage and their eGFR function decreased by at least 25% from baseline.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.